Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischaemic and Safety Events (APPRAISE) trial - Alexander, JH (Circulation, 2009)